There are currently 74 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Autism participants are California, Ohio, Michigan and Illinois.
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
NCT04648202
Recruiting
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Yale University, New Haven, Connecticut +8 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Evaluating Disparities in Precision Oncology
NCT06081517
Recruiting
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Cancer, Advanced Cancer
Register for Updates
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]
NCT05489237
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: University of Miami, Miami, Florida +8 locations
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Register for Updates
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047
Recruiting
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Register for Updates
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +34 locations
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04666688
Recruiting
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: UCLA, Los Angeles, California +11 locations
Conditions: Metastatic Cancer, Solid Tumor, Colorectal Cancer, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer
Register for Updates
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575
Recruiting
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Providence Medical Foundation, Santa Rosa, California +13 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Register for Updates
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029
Recruiting
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: BRCR Global, Tamarac, Florida +5 locations
Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Register for Updates
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Recruiting
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: University of California San Diego, La Jolla, California +2 locations
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Register for Updates
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264
Recruiting
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Honor Health, Scottsdale, Arizona +7 locations
Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Gastroesophageal-junction Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC
Register for Updates
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
NCT05346484
Recruiting
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona +11 locations
Conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
NCT05566574
Recruiting
The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge, New Jersey +6 locations
Conditions: Solid Tumor, Metastatic Cancer
Register for Updates